Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Seremet, Teofila;Brasseur, Francis;Coulie, Pierre
(2011) The Cancer Journal — Vol. 17, n° 5, p. 325-330 (2011)

Files

SEREMET_CANCERJ2011.pdf
  • Restricted Access
  • Adobe PDF
  • 135.2 KB
Request a copy

Details

Authors
  • Seremet, TeofilaUCLouvain
    Author
  • Brasseur, FrancisUCLouvain
    Author
  • Coulie, Pierreorcid-logoUCLouvain
    Author
Abstract
T cell-based cancer immunotherapy relies on advancements made over the last 20 years on the molecular mechanisms underlying the antigenicity of tumors. This review focuses on human tumor antigens recognized by T lymphocytes, particularly the reasons why some are tumor-specific but others are not, and on the immunologic adjuvants used in clinical trials on therapeutic vaccination with defined tumor antigens.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Seremet, T., Brasseur, F., & Coulie, P. (2011). Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. The Cancer Journal, 17(5), 325-330. https://doi.org/10.1097/PPO.0b013e3182326004 (Original work published 2011)